The role of vasoactive intestinal peptide (VIP) in the development of form deprivation myopia (FDM) was examined. Daily intravitreal injection of porcine VIP reduced, but did not eliminate FDM at a maximal daily dose of lx10 -5 mol/injection. A VIP analogue reported to be relatively hydrolysis-resistant in vivo, had no effect on development of FDM at any dose tested. Two VIP antagonists completely abolished FDM. The one reported to be selective for central nervous system VIP receptors was 100 times more potent than one reported to be selective for peripheral nervous system receptors (EDso=2 x 10 -1° and 2 x 10 -s tool/injection respectively). By immunofluorescence using antiserum to porcine VIP, VIP-like immunoreactivity was localized to a subset of amacrine cells (AC) and in three parallel layers in the inner plexiform layer (IPL) (10%, 40% and 70% of IPL thickness from the AC layer). Immunoreactive nerve fibres were also seen in the choroid, the ciliary body and the iris. These results suggest that VIP may play a role in both normal development of the refractive properties of the eye, and in the development of FDM.
INTRODUCTION
Although the effect of form deprivation on ocular growth has now been well characterized, the underlying retinal mechanism and the biochemical factors involved in development of form deprivation myopia (FDM) have yet to be elucidated. Several bioactive substances found in the retina have been implicated in the processes underlying FDM in the chick, including acetylcholine (Stone, Lin & Laties, 1991) , dopamine (Stone, Lin, Laties & Iuvone, 1989; Rohrer, Spira & Stell, 1993a) and basic fibroblast growth factor (bFGF) (Rohrer, Negishi, Tao & Stell, 1993b) . The role of these retinal substances in FDM has been investigated by studying the effect of various agonists and antagonists on the development of FDM.
One retinal peptide that may be involved in ocular growth is vasoactive intestinal peptide (VIP), a highly basic, single-chain peptide containing 28 amino acids, which was originally isolated from porcine gut (Said & Mutt, 1972) . VIP has since been found to be distributed extensively throughout both the central and peripheral nervous systems in most species (Said, 1984) . In the chick retina, VIP has been localized to a subset of amacrine cells (representing about 1% of the total amacrine cell population) (Fukada, Kuwayama, Shiosoka, Inagaki, Ishimoto, Shimizu, Takagi, Sakanaka, Takatsuki, Senba & Tohyama, 1981) . It has been shown immunocytochemically, that retinal VIP levels may be increased in FDM in monkeys (Raviola, Wiesel, Reichlin, Lam & Chetri, 1991) . It has also been found that VIP stimulates apical secretion of proteins of various molecular weights from cultured chicken retinal pigment epithelium (Koh et al., 1991) . Both these findings suggest that VIP warrants investigation as a potential regulator or modulator of eye growth.
The purpose of the current studies was three-fold:
(1)
*Lions Sight Centre, Department of Anatomy, Faculty of Medicine, to characterize pharmacologically the effect of exogenous VIP agonists and antagonists on the development of FDM in the chick; to localize endogenous VIP in the various tissues of the eye, and to determine whether FDM has an effect on the apparent amount of VIP in these tissues; and to identify the origin of VIP-immunoreactive fibers in the eye through immunocytochemical examination of the ciliary ganglion.
MATERIALS AND METHODS

Animals
Male leghorns (Gallus domesticus) were obtained on the day of hatching (Lillydale Hatchery, Linden, Alta). Chicks were housed under fluorescent light on a cycle of 12 hr light, 12 hr dark with light onset at 07:00. Chicks were held for the first week in a large stainless steel brooder, at a room temperature of approx. 25°C. Thereafter chicks were kept in clear Nalgene ~ cages. Chicks were fed water and Purina ~ chick starter ad libitum.
Induction of myopia
Translucent goggles formed from a plastic laminate were attached with cyanoacrylic glue to the skin surrounding the right eye of each chick. Goggles were 22 mm in diameter and 7 mm deep, with a small notch at the top to allow for ocular injections without goggle removal. The left eye was left occluded to serve as a control. Chicks were occluded immediately after injection of the first dose of drug.
In vivo injections
Injections were performed under anaesthesia (1.5% halothane, 50% N20, 50% 02). The animals received daily injections for a period of 8 days into the vitreous chamber of the eye, using a Hamilton syringe with 26 guage needle. Injections were made at 13:00 hr each day, approximately half-way through the light cycle. The injections were carried out between day 10 and day 17. The test substance was injected in 20 #1 of sterile saline. The unoccluded eyes were injected with 20 pl of saline.
Assessment of myopia
At the end of the treatment period, all eyes were assessed for refractive error using a streak retinoscope and trial lenses. Refractive error was assessed to the nearest 0.5 D. A working distance of 0.5 m was used in all cases. Ocular dimensions of the chicks were measured either by using A-scan ultrasonography (Ophthascan "S", Biophysics Medical Inc.) without cycloplegia, or by whole eye measurement with callipers after enucleation. Elimination of myopia was judged to occur when refractive error was eliminated.
Immunoc y t ochemis try
Enucleated chick eyes were bisected along the equator and fixed in Zamboni's fixative overnight at 4°C (Zamboni & DeMartino, 1967 ). The eye halves were then infiltrated with 30% sucrose. Pieces of either the anterior half (including lens, iris and ciliary body) or the posterior half (including sclera, choroid, retinal pigment epithelium and retina) were embedded in OCT compound, frozen, cut in cross-section at approx. 5-7 pm and mounted on gelatin coated slides.
Slides were washed three times for 10 min each in 0.05 M phosphate buffered saline (PBS), then incubated for 30 min with 5% normal goat serum. The primary antibody, a rabbit polyclonal anti-VIP (Epstein) was used at various dilutions. PBS diluent (0.05M PBS pH 7.4_0.3% Triton X-100+0.1% sodium azide) was used in all cases. The slides with primary antibodies were incubated overnight at room temperature. After a further wash in PBS (3 × 10 min), the VIP-like immunoreactivity (IR) was localized by indirect immunofluorescence using a FITC-labelled goat anti-rabbit secondary antibody (Jackson ImmunoResearch Inc., West Grove, Pa).
A possible source of IR fibres in the retina was investigated through staining of the ciliary ganglion. Animals (n=-4) were injected with colchicine [10/~1 of 0.25% (w/v)] into the retrobulbar space. The chicks were sacrificed after 24 hr and the ciliary ganglion removed and fixed for frozen sectioning as described above. Frozen sections (5-7 pm) were mounted on gelatin-coated slides. VIP-like IR was localized as described above.
Specificity of the primary antibody was tested both by comparing results using a second primary antibody (a commercial rabbit polyclonal antiserum from Amersham, Arlington Hts, Ilk) and by preabsorption of the primary antibody with porcine VIP (Sigma Chemical Company, St Louis, Mo.).
RESULTS
Effect of VIP agonists and antagonists on the development of FDM
The effects of intravitreal injection of several VIP agonists and antagonists on development of FDM were tested. Figure 1 shows the mean difference in refractive error between the test (OD) and control (OS) eyes for the lowest daily dose giving the maximum effect for each of the agonists and antagonists tested.
Chicks that received daily injections of saline into both the goggled and the control eyes developed significant myopia in the goggled eye within the 8 day test period. These chicks (n = 6) showed a mean refractive error of -6D
while the control (ungoggled) eyes were emmetropic (0 D of refractive error). There was a mean difference of 0.6 mm in axial length between the goggled eye and the control. The difference in both the axial lengths and the refractive errors between the goggled and the control eye is statistically significant at the 5% level (Student's t-test).
Daily injection of VIP (porcine, Sigma Chemical Company, St Louis, Mo.) led to a decrease in development of FDM in a dose-dependent manner, with an EDs0 of approx. 2 x 10 -s mol/daily injection (Fig. 2) . The maximal dose produced a decrease in refractive error in the goggled eye from -6 to -2 D, and a decrease in difference in mean axial length from 0.6 to 0.25 mm. This represents a maximum decrease in degree of myopia of approx. 66% (based on refractive error) at a daily dose of lx 10 -5 #g in 20#1 of saline, or 6nM maximum concentration to the retina, assuming dilution in a liquid vitreous volume of 150 #1.
VIP has been found to be extremely labile in vivo. Some VIP fragments formed by hydrolysis in vivo (e.g. VIP 10-28) have been found to act as VIP antagonists (Westendorf, Phillips & Schonbrunn, 1983) . Therefore a less labile VIP analogue (Hoffman LaRoche, Nutley, N.J. Peptide RO 246795), expected to yield lesser amounts of antagonistic peptide fragments, was tested. Use of this drug at the EDs0 (2 x 10 -8 mol/injection) found for VIP led to pathological changes in the injected eye, including clouding of both the aqueous and the vitreous humours. Daily injections of this peptide at lower doses (1 × 10-~0 1 x 10-", 1 x 10 -12 mol) had no effect on the development of FDM. The mean difference in eye size, at the highest daily dose tested, was 0.6 mm, the same as the control group. When injected into ungoggled eyes at the doses used above, this peptide did not induce any change in eye size or refractive error. It appeared that a pure VIP agonist had no effect on growth of either normal or form-deprived eyes at the doses given.
These results suggested that the FDM-limiting effect of VIP might be due to the presence of peptide antagonists fragments generated by hydrolysis of injected VIP in vivo. To test this hypothesis, two V1P antagonists were used. The first, a hybrid peptide consisting of the C-terminal of the VIP molecule linked serially to the N-terminal portion of neurotensin, was designed to study VIP effects in the central nervous system (Gozes, McCune, Jacobson, Warren, Moody, Fridkin & Brenneman, 199l) . The second, a modified VIP molecule ([4CI-D-PhC, Leu 17] porcine VIP), was designed and characterized for action in the peripheral nervous system (Pandol, Dharmsathaphorn, Schoffield, Vale & River, 1986) .
Both antagonists reduced development of FDM in a dose-dependent manner (Fig. 3) . However, there was a two orders of magnitude increase in the EDs0 for the "peripheral" antagonist compared to the "central" antagonist (2× 10-1°mol/daily injection for the CNS antagonist vs 2 × 10 -8 mol/daily injection for the PNS antagonist).
To summarize, daily injections of VIP reduced but did not eliminate FDM. A more stable VIP agonist had no effect of development ofFDM. Two VIP antagonists both eliminated the myopia, but with different efficacies. None of these agents had any effect on growth of unoccluded eyes.
Immunoc y t ochemis try
In control eyes, VIP-like immunoreactivity was localized in the retina to cell bodies in the amacrine cell layer, and in three parallel fibre layers at 10%, 40% and 70% depth in the inner plexiform layer (IPL) measured from the amacrine cells [ Fig. 4(a) ]. VIP immunoreactive fibres were also observed in the choroid, the ciliary body and iris masculature [ Fig. 4(b,c) ]. Preabsorption of the diluted antibody with porcine VIP (Sigma) 1 x 10 _5 to 1 × 10 8M) overnight, prior to primary incubation, prevented all staining. A subjective comparison of the brightness of staining was carried out at five different antibody dilutions (1:200, 1:400, 1:800, 1:1600 and 1:3200) in order to assess the relative amount of VIP like immunoreactivity in the myopic and control eyes. These assessments revealed no difference in staining intensity between the myopic and the control eyes, in either the retina, the IPL, the choroid or the iris and ciliary body.
Certain transmitters and peptides, including metenkephalin and dopamine, are synthesized and released from amacrine cells by light-and dark-dependent mechanisms (Iuvone, Galli, Garrison-Gund & Neff, 1978; Luo, Stell & Cupo, 1991) . In order to examine the effects of light and dark on storage and release of VIP, dark-and light-adapted myopic and control eyes were fixed and stained with the VIP antiserum at the same antiserum concentrations as above. There was no evidence of variation in the intensity of staining in any of the tissues examined.
Within the ciliary ganglion and nerves immunoreactive VIP staining was localized to a few fibres. There was no evidence of VIP-IR cell bodies anywhere within the ciliary ganglion, suggesting that the ciliary ganglion is not the origin of the VIP-IR fibres within the retina (Fig. 5) .
DISCUSSION
Development of the refractive properties of the eye in the post hatching chick is dependent on a clear retinal image. Disturbance of this image by application of a goggle over one eye leads to increased growth of the eye and significant myopia. The nature of the biochemical signals involved in both normal growth and in FDM remains unclear.
FDM was partially blocked by daily injections of VIP. When a pure VIP agonist was tested in the same system. FDM was not blocked at any of the three doses tested. When injected into the ungoggled eye this drug had no apparent effect on ocular development. These findings suggest that increasing amounts of exogenous VIP do not directly control ocular growth. However they do not rule out the involvement of endogenous VIP in the development of FDM. The results of screening studies using VIP antagonists support a role for endogenous VIP in the development of FDM. Both of the antagonists tested blocked development of FDM almost completely, although with different efficacies. The blocking effect of both the VIP antagonists is evidence that endogenous VIP plays a role in the development of form deprivation myopia, and that the effect of endogenous VIP can be blocked by a pure antagonist.
The partial rescue effect of porcine VIP observed here may in fact be due to the antagonist effect of VIP fragments. This assumption seems possible, since both antagonists blocked development of FDM, and the VIP analogue known to be less labile in vivo had no apparent effect on development of FDM.
The VIP CNS antagonist (Gozes et al., 1991) was designed to investigate the interaction of VIP with its receptors in the CNS. It has been characterized previously only in the mammalian nervous system. This antagonist was found to inhibit VIP binding and attenuate VIP-stimulated cAMP accumulation in cell cultures derived from mammalian CNS. However, the antagonist is not specific for CNS receptors, having been shown to have some peripheral effects (Gozes et al., 1991) . The peripheral antagonist (Pandol et al., 1986) has been shown to antagonize the action of peptides that interact with the VIP receptor in the exocrine pancreas of the rat. This antagonist to date has not been shown to have an effect in the CNS, although an effect cannot be ruled out.
There are at least two possible explanations for the result observed. First the two antagonists may be exerting their effect at two different sites, one central and one peripheral. Second both antagonists may act at the same site, but with different affinities. The ocular binding site of the two antagonists is currently being investigated.
V|P has a widespread distribution in both the central and the peripheral nervous systems. In the eye, our results confirm localization in both central (the retina) and peripheral (choroid, iris and ciliary body) neural components of the chick eye. Because of this localization it may be possible to study the influence of both the CNS and the PNS on ocular growth and development.
In this study, VIP has been localized in both retina, which is embryologically and anatomically part of the central nervous system, and in peripheral neural components of the eye (choroid, iris and ciliary body) in the chick eye. In the retina VIP was found in a subset of amacrine cells in the retina, and in three layers in the IPL. VIP-IR fibres were also found in the choroid, usually associated with blood vessels. Since VIP is a potent vasodilator, its presence in the vascular choroid is not surprising. Shih, Fitzgerald, Norton, Gamlin, Hodas and Reiner (1993) have demonstrated a reduced choroidal blood flow in chicks wearing goggles that induce myopia. Modulation in release of VIP from nerve fibres in the choroid may have an effect on choroidal blood flow. We found no apparent change in the intensity of staining of the choroidal fibres in this study. However, this method may not be sufficiently sensitive to detect changes in storage and release which may in fact be occurring. For example, if a large reservoir of unprocessed precursor is immunoreactive, changes in release of processed peptide may be undetectable.
The localization of VIP to the choroid, retina, iris and ciliary body does suggest that VIP may have independent effects on several regions of the eye. It may be possible to study the several roles of these systems on ocular growth and development.
Our results suggest that the choroidal VIP immunereactive fibres do not originate from ciliary ganglion cells; the source of these fibres remains to be identified. These findings are surprising, since it has been suggested (at least in the pigeon) that control of blood flow within the choroid is controlled visually by parasympathetic pathways from the nucleus of Edinger-Westphal via projections to the ciliary ganglion (Reiner, Karten, Gamlin & Erichsen, 1983). We are currently examining the superior cervical ganglion of the chick as one alternate source Of VIP-IR fibres in the eye. The role of VIP in regulation of choroidal blood flow warrants further investigation.
No difference was found between the intensity of staining in the myopic eye as compared to the control eye, at any concentration of antibody used. As noted, these methods could not rule out the possibility that FDM might alter the rate of release of VIP. As previously stated the method used in this study may not be sensitive enough to detect small changes in either VIP synthesis or release, especially if a large reserve of VIP precursor is immunoreactive. In rabbits, there is some evidence that receptor sensitivity to VIP may change with the circadian cycle (Kiuchi, Hirota & Gregory, 1993). If FDM had an effect on receptor sensitivity, this may not be reflected in changes in VIP production and release.
Several synaptic transmitters and neuropeptides normally localized in the retina have been shown to be affected by, and to have an effect on, the development of FDM. For example, daytime dopamine levels in the chick are found to drop by about 30% (Stone et al., 1989) in FDM. Apomorphine, a nonspecific dopamine agonist prevents FDM in a dose-dependent manner (Rohrer et al., 1993a, b) . However, no peptide has been shown previously to have definitive control of ocular growth and development. The mechanism of action of these and other neuropeptides remains unclear. It seems likely that ocular growth occurs as a result of interaction between a number of neural subsystems using a variety of intercellular messengers.
